- Details
- Fred Saad joins Alicia Morgans highlighting the efficacy of olaparib versus either abiraterone or enzalutamide, given a potential difference in the efficacy of NHA sequencing that he presented during a podium presentation at the American Urologic Association (AUA) Annual Meeting. The PROfound trial provided a rationale for United States Federal Drug Administration (FDA) approval of olaparib among...
|
- Details
- In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the hormone-sensitive...
|
- Details
- Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...
|
- Details
- In this UroToday discussion, Thomas Keane is joined by Robert Bruce Montgomery to discuss his recent publication, entitled, “Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.” The conversation kicks off with Dr. Montgomery’s “bottom line” for his study, which was to make it easier for oncology providers to find men who can be...
|
- Details
- In this UroToday discussion between Charles Ryan and Mark Markowski, they focus on Dr Markowski’s recent study, entitled COMAT-CRPC. The COMBAT-CRPC study is a study with bipolar androgen therapy and nivolumab, which was conducted through the Prostate Cancer Clinical Trials Consortium. Dr. Markowski begins by discussing the criteria for patient eligibility, which was quite broad, which was to be a...
|
- Details
- Alicia Morgans engages with Michael Morris to delve into the rapidly evolving landscape of radiopharmaceuticals in prostate cancer treatment, highlighting the significance of the VISION data and existing therapies like radium-223. Dr. Morris outlines that the abundance of radiopharmaceutical tools is a "good problem to have," emphasizing that these agents are not one-size-fits-all but have unique...
|
- Details
- Charles Ryan interviews Elena Castro and Fernando Lopez-Campos. They delve into their real-world data on the management of metastatic castration-resistant prostate cancer (mCRPC) in Spain, specifically focusing on the impact of early PSA progression on overall survival in patients treated with enzalutamide or abiraterone. Drs. Castro and Lopez-Campos discuss the significance of monitoring PSA leve...
|
- Details
- The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D. In...
|
- Details
- Emmanuel Antonarakis joins Charles Ryan highlighting the first randomized study to assess high-dose testosterone as a treatment for metastatic castration-resistant prostate cancer (mCRPC). TRANSFORMER (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance) was led by Dr. Samuel R. Denmeade at Johns Hopkins School of Medicine – Sidney Kim...
|
- Details
- In a comprehensive discussion led by Charles Ryan, James Gulley delves into the role of genomic testing and immunotherapy in treating prostate cancer. Dr. Gulley emphasizes the importance of personalized treatment, highlighting studies that identify specific genomic markers like homologous recombination deficiency and mismatch repair deficiency. These markers can guide the use of targeted therapie...
|
